ciltacabtagene autoleucel
janssen
['car-t', 'carvykti']
the second bcma car-t approved, carvykti, has shown it can stay effective at almost 28 months of median follow-up, with overall response rate remaining consistent at 98% among the 97 patients treated. #asco22 
The biopharma world is here. Get the industry’s most comprehensive daily news report at https://t.co/rXFyNyZcJs